Point-of-care technologies for molecular diagnostics using a drop of blood

Yujun Song1,2, Yu-Yen Huang3, Xuewu Liu1,2, Xiaojing Zhang3, Mauro Ferrari1,2, and Lidong Qin1,2

1 Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
2 Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, NY 10065, USA
3 Department of Biomedical Engineering, University of Texas at Austin, Austin, TX 78758, USA

Molecular diagnostics is crucial for prevention, identification, and treatment of disease. Traditional technologies for molecular diagnostics using blood are limited to laboratory use because they rely on sample purification and sophisticated instruments, are labor and time intensive, expensive, and require highly trained operators. This review discusses the frontiers of point-of-care (POC) diagnostic technologies using a drop of blood obtained from a finger prick. These technologies, including emerging biotechnologies, nanotechnologies, and microfluidics, hold the potential for rapid, accurate, and inexpensive disease diagnostics.

Blood as a target for molecular diagnostics

Blood is a bodily fluid that contains abundant information about the health status of the individual. The average human adult has a blood volume of ~5 l continuously circulating throughout the body to deliver necessary nutrients and transport metabolic waste [1]. Blood consists of 54.3% plasma, 45% red blood cells (RBCs), and 0.7% white blood cells (WBCs) by volume [2]. Plasma is composed of proteins, nucleic acids, and nutrients or waste products, and it maintains electrolyte balance and protects the body from infection and blood disorders [3–5]. Serum is produced by removal of blood-clotting factors from plasma [6] and is the main source of samples used in blood-based molecular diagnostics. The levels of molecular constituents in blood are directly associated with the physiological state of the body, therefore, detection of these molecules in serum is often used for prevention, identification, and treatment selection for a variety of diseases.

Traditional technologies for molecular diagnostics in blood include ELISA, PCR, and mass spectrometry (MS) [7]. However, these technologies are limited to laboratory use because they rely on sample purification and sophisticated instruments, are time and labor intensive and expensive, and require highly trained operators. In addition, the sensitivity of some of these technologies is unsatisfactory for detecting trace levels of biomarkers. Therefore, there is still a great challenge to develop simple, inexpensive, rapid, and easy-to-use technologies for POC blood molecular diagnostics. A typical POC assay is affordable, specific, sensitive, portable, rapid, and user friendly, which also makes it suitable for use in low-resource settings [8,9]. The first true POC device was the urine dipstick, which was developed in 1957 to measure urinary protein [8]. Glucose meters and lateral flow devices are currently the most widely used devices in POC blood molecular diagnostics, although they are not applicable if highly quantitative, sensitive, and high-throughput measurements are required. Emerging technologies, including biotechnologies, nanotechnologies, and microfluidics, hold the promise to improve the capabilities for future POC disease diagnostics [10–13].

In this review, we discuss recent developments in new technologies for molecular diagnostics using a drop of blood obtained from a finger prick. Technological developments for low-volume blood diagnostics may facilitate rapid, accurate, and inexpensive diagnosis of disease in the hospital clinic or self-monitoring at home. Taking blood from a finger prick is relatively painless, and it is suitable for POC and pediatric disease diagnostics because of the small samples required. Here, we provide a survey of applicable new technologies for measuring proteins, nucleic acids, and other molecules (e.g., hormones, metabolites, and drugs) as well as downstream molecular analyses based on cancer cells isolated from the blood. We discuss the advantages and disadvantages of each method (Table 1).

Detection of proteins

Proteins are well known to be required for numerous biological functions and processes, ranging from enzymatic reactions to hormone synthesis, maintenance of metabolic equilibrium, and tissue repair [14]. For clinical applications, levels of certain protein biomarkers directly reflect disease stages and have been regarded as one of the most convenient clinical sources for disease diagnosis. Blood
contains >20 000 different proteins, with concentrations ranging from <1 ng/l (troponin) [15] to 50 g/l (serum albumin) [16,17]. Thus, there are abundant blood proteins available as candidate biomarkers for disease detection.

**ELISA-based methods**

Currently, most methods for blood protein analysis are based on ELISA, which serves as the clinical gold standard. In traditional ELISA methods, colorimetric or fluorescent readout signals are used to visualize the binding of a protein to a specific recognition molecule [12]. Despite the development of numerous new ELISA-based technologies for protein detection, many challenges remain to their application in POC diagnostics. Among these are improvements to increase sensitivity, multiplicity, quantification, portability, speed of operation, and clarity of readout, and reduce cost.

The traditional ELISA requires repeated washing steps, which makes the method time consuming and cumbersome. The lateral flow assay (LFA) or immunochromatographic assay, originally introduced in 1987, is considered the most successful commercial technology that overcomes these limitations [18]. This technology combines the principles of thin-layer paper chromatography and ELISA, allowing rapid separation of plasma components in a drop of blood in a few minutes. Recently, a new technology was developed that integrates fluid handling and silver reduction in a microfluidic chip (mChip) and can simplify ELISA. Diagnosis of HIV based on this device requires minimal equipment, analysis can be completed within 20 min, and it requires as little as 1 μl of blood [19]. Although these devices are simple to use, these technologies still exhibit many limitations, such as low sensitivity, results that are only semiquantitative, and low throughput.

The ability to measure low concentrations of disease biomarkers can improve the standard of care in resource-limited areas. Sensitivity can be improved by reducing the ELISA reaction volume to ensure a high concentration of fluorescent substrate [20]. By confining the fluorophore-generation reaction to 50 fl, a digital ELISA method was developed to detect proteins in serum at subfemtomolar concentrations. An alternative method to improve sensitivity is to introduce new signal amplification approaches into ELISA. Controlling the growth of gold nanoparticles (AuNPs) by catalase results in a color change, and its incorporation into an ELISA method (plasmonic ELISA)

### Table 1. List of POC platforms for molecular diagnostics

<table>
<thead>
<tr>
<th>Platform</th>
<th>Affordable</th>
<th>Specific</th>
<th>Sensitive</th>
<th>Portable</th>
<th>Rapid</th>
<th>Multiplex</th>
<th>Quantitative</th>
<th>User-friendly</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proteins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ELISA-based methods</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LFA</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td></td>
<td></td>
<td>[18]</td>
</tr>
<tr>
<td>Integrative mChip</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td></td>
<td></td>
<td>[19]</td>
</tr>
<tr>
<td>Digital ELISA</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td></td>
<td></td>
<td>[20]</td>
</tr>
<tr>
<td>Plasmonic ELISA</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td></td>
<td></td>
<td>[21]</td>
</tr>
<tr>
<td>Silicon nanoribbon chip</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td></td>
<td></td>
<td>[22]</td>
</tr>
<tr>
<td>GMR sensor</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td>[23]</td>
</tr>
<tr>
<td>IBBC</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td>[24,25]</td>
</tr>
<tr>
<td>P-ELISA</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td>[26–28]</td>
</tr>
<tr>
<td>V-Chip</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td>[29]</td>
</tr>
<tr>
<td><strong>Non-ELISA-based methods</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPS</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[32]</td>
</tr>
<tr>
<td>GFP–AuNPs</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td></td>
<td></td>
<td>[31]</td>
</tr>
<tr>
<td>AuNPs (colorimetric)</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td></td>
<td></td>
<td>[33]</td>
</tr>
<tr>
<td>AuNPs (DLS)</td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td>[34,35]</td>
</tr>
<tr>
<td><strong>Nucleic acids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>μCICS</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[44]</td>
</tr>
<tr>
<td>TAm-Seq</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[45]</td>
</tr>
<tr>
<td>CCP</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[46]</td>
</tr>
<tr>
<td><strong>RNA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPD-SENS</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[48]</td>
</tr>
<tr>
<td>EMRS</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[50]</td>
</tr>
<tr>
<td>Nanopore sensor</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[51]</td>
</tr>
<tr>
<td><strong>Other types of biomolecules</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graphene glucose sensor</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[52]</td>
</tr>
<tr>
<td>PGM–aptamer sensor</td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
<td>[56]</td>
</tr>
<tr>
<td>DMF</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[57]</td>
</tr>
<tr>
<td>Amperometric sensor</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[60]</td>
</tr>
<tr>
<td><strong>CTCs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunomagnetic assay</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td></td>
<td></td>
<td>[66]</td>
</tr>
<tr>
<td>Immunoassay chip</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[67–70]</td>
</tr>
<tr>
<td>Size-based microchip</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[71]</td>
</tr>
<tr>
<td>Dielectric separation</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>[73]</td>
</tr>
</tbody>
</table>

+++ high; ++, intermediate; +, low. Data for blank cells are not traceable through literature search.
results in ultrasensitive detection of blood proteins [21]. The detection limit in serum for spiked prostate-specific antigen and HIV-1 capsid antigen (p24), which is observable by a color change, is as low as $10^{-18}$ g/ml. Other efficient methods for highly sensitive detection are based on reducing the background signal. The microfluidic purification chip is able to capture protein biomarkers from blood and then release them into buffer for sensing based on silicon nanoribbon detectors [22]. Magnetic signal-based ELISA platforms (GMR sensors) avoid detectable magnetic background signals, produce low noise signal [23], and can detect attomolar concentrations of proteins in serum over a range of more than six orders of magnitude. However, these technologies are time consuming to operate and require sophisticated instruments to read the results.

Clinical research has proven that multiprotein quantitative measurements provide more accurate diagnostic results. mChips fabricated using photolithography show powerful applications in multiplex protein assays [12]. The recently introduced integrated blood barcode chip (IBBC) uses microscopic fluorescent barcodes as reporter signals for multiplex assays of blood [24,25]. Paper-based ELISA (P-ELISA) has also been used to assay liver injury-related enzymes in human blood [26–28]. However, quantitative measurement still requires sophisticated instruments. The multiplexed volumetric bar-chart chip (V-Chip) integrates ELISA reactions with volumetric measurements of oxygen generated on a mChip (Figure 1), allowing instant and visual quantitation of biomarkers [29]. In addition, the V-Chip generates the visible bar chart without additional instrumentation, data processing, or graphic plotting. After a simple oblique sliding of the upper plate over the lower, the advance of ink in each individual channel indicates the amount of catalase that reacted in that well, which correlates with the concentration of the corresponding ELISA target protein. The V-Chip approach enables multiplex, quantitative measurement of target protein biomarkers. The sensitivity could be amplified by depositing multistage uniform platinum films in the device [30]. In the future, the technology may show wide application by integrating sample pretreatment in the device.

Non-ELISA-based methods

The traditional clinical method for total serum analysis is electrophoresis combined with MS [31]. However, sensitivity and quantification remain issues for clinical applications. Effort is still needed to develop new optimal technologies for overall serum analysis. Thin films of mesoporous silica (MPS) were found to enhance enrichment of the circulating low-molecular-weight proteome (LMWP) from serum. The captured LMWP is then detected and analyzed by MS [32]. Nevertheless, MS is too expensive for use in POC diagnostics. In addition to MS, a new sensing platform relying on electrostatic interactions between GFP and AuNPs has recently been developed for sensing proteins in serum [31]. The GFP–AuNP conjugate mimics protein–protein surface interactions, and this is instrumental in reaching detection limits sufficiently low to measure biomedically relevant changes in protein concentration in undiluted human serum. Antibody-labeled AuNPs will aggregate in the presence of protein targets, which exhibits colorimetric or light scattering signals [33–35]. Colorimetric detection methods show promise for use in POC diagnostics because the signal is detectable by the naked eye, whereas dynamic light scattering (DLS) is able to detect low concentrations of biomarker proteins. These assays are rapid and do not require any washing steps. However, direct analysis of proteins in blood requires further improvement and optimization.

Detection of nucleic acids

Nucleic acids are the intracellular carriers of genetic information [36–39] and are also found in small amounts in healthy and diseased human serum [40]. These circulating nucleic acid molecules are thought to be released from

Figure 1. V-Chip for detection of protein biomarkers. (A) Schematic design of the V-Chip. The left image shows assembled V-Chip, preloaded with ink and H$_2$O$_2$; ELISA is performed in the indicated lanes. Oblique sliding (arrow) of the upper plate across the lower plate interrupts the horizontal flow path, forming isolated vertical channels in which catalase and H$_2$O$_2$ react to generate oxygen and propel ink through the channels. (B) ELISA reaction and mechanism of oxygen generation. (C) V-Chip can be loaded with 50 different antibodies using swab tips. Scale bar, 0.5 cm. (D) High-magnification microscopic images of typical operating steps in a 50-plex V-Chip. Scale bar, 2.5 mm. V-Chip, volumetric bar-chart chip. Reproduced, with permission, from [29].
dying cells as they break down \cite{41,42}, and their extraction and analysis from a drop of blood provides a relatively noninvasive, highly patient-compliant method for detection of genetic disease states. Current methods for detection of nucleic acids are mainly based on PCR, which limits use to the laboratory, and they are still relatively expensive and cumbersome. Although microfluidic devices provide the opportunity for rapid purification of nucleic acids from blood \cite{43}, a great challenge remains in integrating blood pretreatment with nucleic acid detection in an inexpensive, robust, and user-friendly format.

**Measurement of DNA**

Circulating DNA may arise from apoptotic or necrotic cells and is regarded as a noninvasive biomarker for a diverse array of human diseases. Analysis of fragment size shows promise for identification of DNA source in cancer and prenatal diagnostics. A microfluidic single-molecule spectroscopy technique (microcylindrical illumination confocal spectroscopy; μCICS) has been developed to analyze DNA biomarkers directly in serum \cite{44}. This new technology allows for one-step analysis and quantification of circulating DNA in volumes <1 pl of serum with no additional steps required for DNA isolation or enzymatic amplification.

Identification of DNA mutations using serum samples is another important aspect for cancer therapy, because mutations can modulate the effectiveness of biological reagents on target-specific pathways \cite{45}. Circulating DNA extracted from the serum of cancer patients always contains tumor-specific mutations. A new method to amplify and sequence large genomic regions from as little as a single copy of circulating DNA, tagged-amplicon deep sequencing (TAm-Seq) has been developed. It was found that the high sensitivity and specificity of TAm-Seq enables detection of mutation rates as low as 2\% when 5995 nucleotides were screened.

Methylated DNA is another promising biomarker for early detection of cancer and other genetic diseases. Combinations of changes in methylation show stronger associations with specific cancers than single alterations. Recently, a fluorescence resonance energy transfer method based on a water-soluble cationic conjugated polymer (CCP) was used to quantitate cellular DNA methylation levels in colon cancer patients \cite{46}. This method exhibited high accuracy and sensitivity in discriminant analysis and cumulative detection. In the future, this technology may be extended to detect methylation of circulating DNA.

**Measurement of RNA molecules**

miRNAs are small (∼22 nucleotides) regulatory RNA molecules that are frequently dysregulated in cancer and are promising candidates for biomarkers for cancer classification and prognosis \cite{47}. Detection of miRNA in blood with high (at least femtomolar) sensitivity remains a challenge. Recently, a three-mode electrochemical sensor (HPD-SENS) with low detection limit and wide dynamic range was developed for quantitative detection of miRNA. The sensor can detect as little as 5 aM miRNA, with a dynamic range of 10 aM to 1 μM \cite{48}. Nanotechnology-based methods have been used to design highly sensitive sensors for miRNA detection \cite{49}. DNA nanostructures can improve the sensitivity of an electrochemical miRNA sensor (EMRS), which is able to detect miRNAs at concentrations as low as attomolar \cite{50}. In addition, a nanopore sensor based on the protein α-hemolysin was developed for detection of miRNAs in samples of plasma from lung cancer patients (Figure 2). This nanopore-based miRNA sensor can quantitate cancer-associated miRNAs at subpicomolar concentrations, as well as distinguish single-nucleotide differences \cite{51}.

---

**Figure 2.** Nanopore-based sensor for miRNA analysis. (A) Schematic diagram of miRNA and probe used in nanopore sensor. (B) Signal for detection of miR-155. Red boxes show multilevel current pattern. (C) Signals (left) and corresponding molecular mechanism (right) of miR-155–probe hybrid dissociation and translocation in the nanopore cavity. Reproduced, with permission, from \cite{51}.
Detection of other types of biomolecules

Other types of biomolecules in blood come from metabolic processes or drug use. The levels of metabolites, including hormones and blood chemicals, are often indicators of disease, whereas the presence of addictive drugs, such as cocaine, in the blood, is often monitored to detect and prevent drug abuse and illicit trafficking [8]. Because of small size or similar chemical structure, commercially available antibodies recognizing these molecules always exhibit high cross-reactivity in immunoassays. Therefore, existing methods for detection of small molecules often lack sufficient sensitivity or specificity.

Measurement of blood glucose is crucial to maintain the normal physiological range in controlling diabetes mellitus. The first glucose sensor for home use was marketed in 1981. Current glucose meters rely primarily on measuring the electrochemical signals [8]. Additional colorimetric glucose sensors based on the intrinsic peroxidase-like activity of graphene have also been developed [52]. Measurement of blood glucose using these devices is simple, inexpensive, and highly sensitive and selective. Other carbon nanomaterials, such as carbon nanotubes or graphene–hemin complexes, also exhibit peroxidase-like activity and could be used for detection of copper ions, DNA, lysozyme, and cancer cells [29,53–55].

By combining the technology underlying personal glucose meters (PGMs) with newer functional DNA sensors, a new device has been developed that is able to detect quantitatively cocaine in blood and serum (Figure 3) [56]. This method shows high sensitivity, with detection limit of \( \sim 1.0 \mu \text{g/ml} \). Other targets, including adenosine, interferon-\( \gamma \), and toxic metal ions, can be detected by changing the sequence of the functional DNA.

The steroid hormone estrogen is often used to identify women at risk for breast cancer or to monitor antiestrogen therapy in breast cancer [57]. A compact, efficient, and intuitive method has recently been devised for estrogen analysis in blood samples as small as 1 \( \mu \text{l} \). The underlying principle of digital microfluidics (DMF) involves movement of a sample through a set of electrodes by applying electric current. The method may be applied to most multistep sample-processing procedures and used for analysis of blood and serum samples [58,59].

Nitric oxide (NO) is a metastable free radical synthesized by NO synthetases and involved in important physiological processes, such as wound healing, angiogenesis, and immune response [60]. A new microfluidic device based on a NO-selective xerogel polymer measures NO in small (250 \( \mu \text{l} \)) blood samples. This amperometric sensor shows excellent selectivity and high sensitivity, with detection limit of 840 pM in phosphate-buffered saline and 472 nM in blood.

Cell based molecular analyses

Circulating tumor cells (CTCs) shed from the primary tumor site and present in the bloodstream provide a rare model system for potential downstream molecular analyses to understand the mechanism of cancer development. Advanced technologies developed in genomics and proteomics can be further applied to determine the activity...
patterns of genes and proteins in different types of cancerous or precancerous cells. Such molecular signatures can significantly improve the clinician’s ability to diagnose and manage cancer.

CTCs are rare (1 in $10^7$–$10^9$ blood cells), which poses significant challenges for capture. Clinical applications would require novel platforms for such noninvasive ‘liquid biopsy’ with high capture efficiency and sensitivity, and low cost. Among the recent developments in this area, microfluidic technology, immunomagnetic assay, and molecular analysis have been integrated to fulfill such a requirement. A commercial, FDA-approved screening system (CellSearch) has been developed for the enumeration of CTCs in samples of whole blood. Integration of an immunomagnetic assay with a microchip is a widely used cell isolation method whereby magnetic force is applied to separate cancer cells (e.g., CTCs), labeled with magnetic particles, from unlabeled RBCs and WBCs for further molecular analysis. In this approach, magnetic particles/beads coated with antibodies specific for antigens expressed on cancer cells are used to tag target cells for magnetic capture (Figure 4) [61–66]. Dendrimers, polymer nanofibers, graphene, and other nanomaterials have also been introduced in mChips to increase capture efficiency [67–70]. Other than immunolabel-based isolation methods, label-free microfluidics-based methods have been proposed for application to cell separation. A size-based microchip has been developed to isolate cancer cells from other blood cells based on differences in physical properties, such as size, shape, density, and deformability of each cell type [71,72]. Other label-free isolation technology, such as that exploiting dielectric properties of cancer cells, can be applied for separation purposes [73].

To analyze the cells and acquire genomic information, such as cancer stage, epithelial to mesenchymal transition status of cancer cells, and molecular biomarkers for different cancer types, DNA and RNA are extracted from the collected cells. Several methods, such as fluorescence in situ hybridization (FISH), RT-PCR, quantitative RT-PCR (qRT-PCR), and digital PCR have been used for the molecular analysis of cancer cells to provide diagnostic and prognostic information for cancer treatment strategies (Figure 4D) [74–77].

Concluding remarks and future perspectives
Molecular diagnostics provide the signatures of diseases throughout their development. As more blood biomarkers are discovered, diagnosis of disease by determining levels of proteins, nucleic acids, small molecules, or cell derived molecules in blood remains an exciting area of modern medicine. In this review, we have presented an overview of recent developments in molecular diagnostic technologies that are applicable to a single drop of blood obtained by a simple finger prick. These new diagnostic technologies use optical, electronic, or other readable signals. Remaining challenges with some of these new molecular technologies include problems of consistency and reliability, and further optimization will be required before commercialization becomes feasible.

The future development of POC molecular diagnostics will be driven by the needs of resource-limited areas, such as developing countries or in the home, where insufficient health care facilities exist for diagnostic support. Therefore, low cost, delivery capability, and user-friendliness of the technologies are the main issues to be addressed in the future. In general, developments in nanotechnology and biotechnology have clearly improved the sensitivity and

![Figure 4. CTC isolation and downstream molecular analyses. (A) Anti-EpCAM-conjugated ferrofluids were used to tag CTCs for magnetic separation. (B) A microchip-based immunomagnetic isolation system was proposed for separating magnetic-particle-labeled CTCs from other blood cells in whole blood samples for fluorescence analysis. (C) Other microchip-based approaches using nanomaterial-assisted, size-, mechanical-property-, and electrophoresis-based microchips can also be used to isolate CTCs, WBCs, and RBCs simultaneously for downstream analysis. (D) Downstream gene expression analysis of DNA or RNA extracted from captured CTCs using RT-PCR, quantitative (q)RT-PCR, digital PCR, or FISH [74–77]. Abbreviations: NP, nanoparticle; CTC, circulating tumor cell; Ep-CAM, epithelial cell adhesion molecule; FISH, fluorescence in situ hybridization; RBC, red blood cell; WBC, white blood cell. Reproduced, with permission, from [74–77].](image-url)
specificity of molecular diagnostics. However, these improvements were accompanied by sacrifices in cost and portability because they often require labor-intensive sample pretreatment and sophisticated instruments for reading results. mChips allow considerable throughput, portability, and the capacity for a high level of integration, thus, they will fulfill the requirements of POC molecular diagnostics if sample preparation and advanced nanotechnologies/biotechnologies are introduced. Meanwhile, device costs may be reduced by use of inexpensive materials, small volumes of reagents, and massive levels of production.

References
3 Huang, S.J. et al. (2006) Clinical experience of hydroxyethyl starch (10% HES 200/0.5) in cerebral perfusion pressure protocol for severe head injury. Surg. Neurol. 66 (Suppl. 2), S26–S31
30 Song, Y. et al. (2013) A multistage volumetric bar chart chip for visualized quantification of DNA. J. Am. Chem. Soc. 35, 16785–16788
38 Lam, B. et al. (2013) Solution-based circuits enable rapid and multiplexed pathogen detection. Nat. Commun. 4, http://dx.doi.org/10.1038/ncomms3001
64 Hoshino, K. et al. (2011) Microchip-based immunomagnetic detection of circulating tumor cells. Lab Chip 11, 3449–3457
66 Chen, P. et al. (2014) Multiscale immunomagnetic enrichment of circulating tumor cells: from tubes to microchips. Lab Chip 14, 446–458
73 Gascogne, P.R. et al. (2009) Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 30, 1388–1398
76 Lim, L.S. et al. (2012) Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. Lab Chip 12, 4388–4396